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Mitochondria are best known as the powerhouses of the cells but their cellular role goes
far beyond energy production; among others, they have a pivotal function in cellular
calcium and redox homeostasis. Mitochondrial dysfunction is often associated with
severe and relatively rare disorders with an unmet therapeutic need. Given their central
integrating role in multiple cellular pathways, mitochondrial dysfunction is also relevant
in the pathogenesis of various other, more common, human pathologies. Here we
discuss how live-cell high content microscopy can be used for image-based phenotypic
profiling to assess mitochondrial (dys) function. From this perspective, we discuss
a selection of live-cell fluorescent reporters and imaging strategies and discuss the
pros/cons of human cell models in mitochondrial research. We also present an overview
of live-cell high content microscopy applications used to detect disease-associated
cellular phenotypes and perform cell-based drug screening.
Keywords: mitochondrial disease, pathological phenotype, cell models of disease, assay development, live cell
microscopy, fluorescent probes, HCS, cellomics
INTRODUCTION
Mitochondrial diseases can result from mutations in the nuclear (nDNA) or mitochondrial DNA
(mtDNA). These mutations often lead to disruption of mitochondrial function and/or (ultra)
structure leading to “primary mitochondrial disorders” (Koopman et al., 2012) that are progressive,
multisystemic and relatively rare (prevalence ∼1:5000) (Parikh et al., 2015). Mitochondrial
dysfunction is also a hallmark of various neurodegenerative disorders like Alzheimer’s, Parkinson’s,
and Huntington’s disease, cardiovascular disease, cancer, diabetes, and epilepsy (Koopman et al.,
2012). Mitochondrial dysfunction can also be triggered by environmental factors (Meyer et al.,
2013) and off-target drug effects (Schirris et al., 2015).
Mitochondrial function operates at the junction of numerous cellular signaling and
metabolic pathways. At the metabolic level, the tricarboxylic acid cycle together with the
four complexes (CI-CIV) of the electron transport chain (ETC) and the FoF1-ATP synthase
(or CV) converts food-derived metabolites into ATP. This process consumes oxygen (O2)
and establishes a membrane potential (1ψ) across the mitochondrial inner membrane
(Mitchell, 1961). But mitochondria are also key players in cellular redox homeostasis, calcium
signaling, branched-chain amino acid metabolism and the coordination of lipid biosynthesis
(Nunnari and Suomalainen, 2012).
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In this review, we summarize how live cell analysis
using fluorescent reporter molecules and (semi)quantitative
microscopy can be used to analyze mitochondrial phenotypes.
We also discuss various cellular models of mitochondrial
disease with respect to their benefits, disadvantages, technical
applicability and appropriateness as a disease model. Finally,
we present a collection of high-content microscopy strategies to
evaluate mitochondrial contribution to disease and to perform
drug toxicity and efficacy screening.
LIVE IMAGING OF CELL-BASED
READOUTS TO MEASURE
MITOCHONDRIAL FUNCTIONS
Various experimental methodologies quantify mitochondrial
dysfunction by focusing on activity measurements of specific
mitochondrial enzymes and/or pathways following tissue/cells
homogenization and/or using isolated mitochondria (Picard
et al., 2011). By contrast, live-cell microscopy assays have
the advantage to visualize and quantify functional and
structural (sub)cellular (spatial dimension) components
in situ in living cells. Moreover, microscopy uniquely allows
for simultaneous time-lapse monitoring (temporal dimension)
and (semi)quantitative measurements of multiple parameters
by multispectral imaging (spectral dimension). In particular,
developments in fluorescent reporter technology tremendously
boosted the use of light microscopy for cell biology studies
(Sbalzarini, 2016).
A limitation of fluorescent microscopy is the potential
induction of phototoxic stress, which can be caused by
illumination of the reporter molecules. Moreover, fluorophores
themselves can perturb the physiological function of
biomolecules and are subjected to photobleaching. Furthermore,
due to calibration limitations, quantification of cellular
parameters using single wavelength dyes can be challenging
and, in some cases, only relative and qualitative measurements
are possible. The application of ratiometric dyes, when possible,
takes care of variable dye loading and extrusion responding with
a (semi)quantitative change in fluorescence upon target binding.
A drawback of the ratiometric dyes is related to their portability
to high-throughput where doubling data dimension can create
acquisition, storage and processing issues. Implementing
ratiometric dyes in multispectral assays can be also inconvenient
because of the wavelength limitation.
When mitochondrial contribution to disease is evaluated
in living cells, we consider mitochondrial morphology and
membrane potential, ROS, ATP and mitochondrial respiration
crucial indicators of mitochondrial health status. Their
compatibility with fluorescence microscopy assays will be
presented in the next paragraphs and is summarized in Table 1.
Mitochondrial Morphology and 1ψ
Mitochondrial dysfunction is often associated with simultaneous
aberrations in mitochondrial morphology (e.g., fragmentation,
roundness) and membrane potential (1ψ). Fluorescence
live-cell imaging is the most direct method for assessing
their spatiotemporal dynamics (Koopman et al., 2008).
Different lipophilic cell-permeant, cationic and fluorescent
molecules have been presented, which diffuse across the
plasma membrane of the cell and accumulate in the
mitochondrial matrix in a 1ψ dependent manner. These
molecules include tetramethylrhodamine methyl ester (TMRM),
tetramethylrhodamine ethyl (TMRE) ester, rhodamine 123,
DiOC6(3) (3,3′- dihexyloxacarbocyanine iodide), JC-1 (5,5′,6,6′-
tetrachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine
iodide), and the MitoTracker R© family. Among these molecules,
TMRM was described to be the least toxic, the fastest in
equilibrating across membranes, and displaying the lowest
non-specific localization (Nicholls, 2012; Zorova et al.,
2018). Therefore in our research we generally use TMRM
to simultaneous analyze mitochondrial morphology and 1ψ
referred to as mitochondrial morphofunction (Koopman et al.,
2008; Iannetti et al., 2016). The cell types, staining, imaging
conditions and descriptors applicable for the analysis of
mitochondrial morphofunction have been previously reviewed
(Iannetti et al., 2015; Zorova et al., 2018) and are summarized
in our recent study (Iannetti et al., 2016). To technically
validate measurements of 1ψ using TMRM, we performed
oligomycin/bongkrekic acid, rotenone and FCCP acute
injections while kinetically measuring mitochondrial TMRM
fluorescence fluctuations (Iannetti et al., 2016). Although TMRM
measurement, even under highly standardized experimental
settings, have been considered still semi-quantitative (Leonard
et al., 2015; Nicholls, 2018) attempts using this dye to perform
more absolute measurements have been performed combining
it with the analysis of the plasma membrane potential
(Gerencser et al., 2016).
Protein-based probes targeted to the mitochondria, such
as mito-GFP, are also a valid tool to study mitochondrial
morphology and dynamics (Rizzuto et al., 1995; Nomura et al.,
2009), however, these do not allow the simultaneous study of1ψ.
Reactive Oxygen Species
Reactive oxygen species (ROS) is a general term that includes
both oxygen radicals and non-radical agents that can be easily
converted into radicals (Halliwell and Gutteridge, 1985). ROS
are generated both in the cytosol and in mitochondria as (by)
products of normal physiological cell metabolism (Murphy, 2009;
Forkink et al., 2010). Depending on the chemical nature of the
ROS, the location at which they are generated and their (local)
concentration, ROS can exert a signaling role or induce oxidative
and/or redox stress (Lin and Beal, 2006; Smeitink et al., 2006)
emphasizing the importance to determine their concentration,
types, and localization with precision (Woolley et al., 2013).
Several non-microscopy based approaches are
available (e.g., mass spectrometry, western blotting, and
immunohistochemistry) to indirectly study ROS via the
quantification of the accumulated reaction products (oxidized
protein, lipid, and DNA) (McDonagh, 2017; Teixeira et al.,
2018). Due to this accumulation these methods have an high
sensitivity, however, they do not consider the spatial and
temporal dimensions because cell lysates are usually analyzed at
end points.
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TABLE 1 | Live imaging cell-based mitochondrial readouts and probes.
Readouts and probes Pros and cons A B C D E
Mitochondrial morphology and 1ψ
TMRM (or TMRE) Pros: fast equilibration, low non-specific bindings, low ETC
inhibition, low toxicity.
c m 553 576 Iannetti et al., 2016
rhod 123 Pros: can be used in quenching mode for fast resolving
studies to monitor acute changes in 1ψ.
c m 507 529 Perry et al., 2011
DiOC6(3) Cons: non-specific binding. c m 489 506 Perry et al., 2011; Zorova et al.,
2018
JC-1 Pros: JC-1 aggregates emit at different λ discriminating
high and low 1ψ. Cons: Inconsistent experimental data.
c d 498 525/595 Zorova et al., 2018
MitoTracker Pros: retained after cell fixation.
Cons: not suitable for 1ψ live monitoring.
c m ∗ ∗ Chazotte, 2011
ROS
CM-H2DCFDA Cons: target aspecificity, no subcellular targeting. c m 495 529 Chen et al., 2010
DHE Cons: target aspecificity, no subcellular targeting. c m 480 520 Zielonka and Kalyanaraman,
2010
MitoSOX Pros: mitochondrial localization. Cons: target aspecificity. c m 510 580 Zielonka and Kalyanaraman,
2010
BODIPY 581/591 C11 Pros: intracellular membrane lipid targeting. c d 500/650 510/665 Pap et al., 1999
MitoPerOx Pros: BODIPY 581/591 C11 properties with mitochondrial
localization and faster equilibration.
c d 580/600 590/520 Prime et al., 2012
rxYFP Cons: pH sensitivity, target aspecificity. g m 513 527 Meyer and Dick, 2010;
Pouvreau, 2014
roGFP Pros: minor pH sensitivity than rxYFP, possibility to perform
kinetic studies for long-lasting redox changes.
g d 400/480 510 Meyer and Dick, 2010;
Pouvreau, 2014
HyPer Pros: specific indicator of H2O2. Cons: pH sensitivity. g d 420/500 516 Meyer and Dick, 2010; Bilan
and Belousov, 2016
ATP
ATeam Cons: phototoxicity during long-time observation, pH
sensitivity.
g d 435 527/475 Imamura et al., 2009
BTeam Pros: increased detection sensitivity, reduced phototoxicity
for long kinetic measurement than ATeam.
g d 460 455/527 Yoshida et al., 2016
ARP-1 Pros: pH independent, higher sensitivity, higher selectivity to
distinguish ATP from its analogs.
c m 500 557 Sunnapu et al., 2017
RSL+ Pros: mitochondrial localized, higher sensitivity, higher
selectivity to distinguish ATP from its analogs.
c m 520 583 De la Fuente-Herreruela et al.,
2017
General pros of genetic probes are: specifically targeted to different subcellular locations. General con of genetic probes is: transfection is required. General pros of
ratiometric dual-wavelengths probes: quantitative measure is possible. A. Type of probe: Chemical (c) or genetic (g), B. mono-wavelength (m) or dual-wavelength (d). C.
Maximal excitation wavelength. D. Maximal emission wavelength. E. References. ∗The MitoTracker R© family includes several dyes with different spectral properties (e.g.,
MitoTracker Red Ex: 579, Em: 599; MitoTracker Green Ex: 490 Em: 516). λ = wavelength.
A wide range of chemical or proteinaceous fluorescent ROS
probes has been developed (Zhang and Gao, 2015). The two
most commonly used chemical ROS probes are 5-(and-6)-
chloromethyl-2,7-dichlorodihydrofluorescein diacetate
(CM-H2DCFDA) (Chen et al., 2010) and dihydroethidium
(DHE) (Zielonka and Kalyanaraman, 2010). While
CM-H2DCFDA was initially developed and used to specifically
detect H2O2 and DHE for superoxide detection, growing
evidence indicates that these are both non-specific ROS
indicators that should be used for qualitative analysis of
total cellular oxidant stress rather than for specific ROS
types (Koopman et al., 2006; Chen et al., 2010; Zielonka and
Kalyanaraman, 2010). Despite that, they currently are the
most popular ROS sensors because of their technical ease
of use that no alternatives can yet guarantee. Especially for
CM-H2DCFDA a rigorous monitoring of the experimental
setup and in particular of the protection from environmental
light, which is more easily executed with automated imaging, is
required. Under tight quality controlled conditions these dyes
can produce meaningful and robust qualitative information
related to intracellular ROS bursts.
MitoSOX, which is DHE linked to a TPP moiety for rapid
accumulation in mitochondria, would ideally allow detection
of mitochondria specific ROS production (Robinson et al.,
2006). However, this dye needs to be used with caution, since
oxidation of the probe may have happen before it enters the
mitochondria (Connolly et al., 2017). Furthermore, the oxidized
probe tends to bind to DNA upon which its fluorescence is much
increased (Mukhopadhyay, 2008). In our experiments we take
especial care to monitor the acquired images and exclude all
data in which the staining is not strictly mitochondrial (Beyrath
et al., 2018). Flow cytometric and plate reader experiments
using mitoSOX should therefore be avoided or interpreted
with great care.
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Lipid peroxidation of the mitochondrial inner membrane
represents a major cause of mitochondria disruption (Morris
et al., 2018; Nielson and Rutter, 2018) and ferroptosis cell
death (Yang and Stockwell, 2016) and it is also considered a
crucial readout for evaluation of mitochondrial dysfunction.
A ratiometric fluorescent probe, MitoPerOx, specific for
mitochondrial fatty acid peroxidation was developed (Prime
et al., 2012). MitoPerOx is the mitochondrial targeted version
of the BODIPY 581/591 C11 used for the measurement of
peroxyl radicals in the general cellular membrane fraction
(Pap et al., 1999).
The major drawbacks of the currently available chemical
fluorescent ROS probes are the non-specific photo- and
chemical-oxidation and the limited availability of subcellular
targeting options. This often causes an unclear temporal
resolution dynamic: it is not clear where the oxidation
of the probe happened. To overcome this limitation,
genetically encoded ROS indicators have also been developed:
redox-sensitive yellow fluorescent proteins (rxYFP family),
redox-sensitive green fluorescent proteins (roGFP family)
and the H2O2 probe HyPer (Pouvreau, 2014). The working
principle of rxYFP and roGFP is based on a change in the
oxidation state of the redox-reactive cysteines group that
induces a conformational change in the fluorescent properties
of the sensor protein (Meyer and Dick, 2010). HyPer instead
works by an H2O2-sensing regulatory domain of a prokaryotic
transcription factor which cysteine active site readily reacts
with H2O2 inducing a conformational change of the fluorescent
protein (Bilan and Belousov, 2016). These genetically encoded
ROS and redox indicators have the advantage of providing more
reliable real-time monitoring of specific ROS in subcellular
compartments. However, using genetically encoded chimeric
proteins that require cell transfection and gene expression,
can be technically challenging depending from the cell type
(Kim and Eberwine, 2010).
ATP
ATP plays a central role in bioenergetics and intra/inter-cellular
signaling. It can be considered an indicator of cellular and
mitochondrial health status (Koopman et al., 2012). A number
of well-established assays such as HPLC-based methods and
biochemical assays based on luciferase-luciferin bioluminescence
guarantee high specificity and accuracy to measure ATP (Vives-
Bauza et al., 2007), however, these approaches are not applicable
to study living cells because they require the physical extraction
of the ATP from the cells by cell homogenization procedures.
Currently, luciferin-luciferase bioluminescence assays using
plate readers represent still the gold standard to measure
ATP in cells and robust kits are commercially available from
different providers.
Significant advances have been made to image ATP using
fluorescent, chemiluminescent, bioluminescent and resonance
energy transfer technologies based on genetically encoded or
chemical probes. Genetic approaches provide great flexibility
in the subcellular localization to be targeted. In particular the
fluorescence resonance energy transfer (FRET) sensors of the
ATeam family (Imamura et al., 2009) that consist of a subunit
of the bacterial FoF1-ATP synthase combined with fluorescent
proteins of different colors, were developed to differentially
target cytosol, nucleus or mitochondrial matrix and have been
validated in several studies (Liemburg-Apers et al., 2011; Forkink
et al., 2014). BTeam the next generation genetically encoded
sensors to image ATP, have increased detection sensitivity and
allow kinetic measurement of cytosolic ATP levels of the same
cells (Yoshida et al., 2016).
Chemical probes that passively diffuse into the cells, such as
the rhodamine-based chemical sensors, ARP-1 and RSL+, have
been recently developed for real-time imaging of mitochondrial
ATP in living cells (De la Fuente-Herreruela et al., 2017;
Sunnapu et al., 2017).
To the best of our knowledge, no chemical ATP probes are
currently commercially available. Because ATP concentrations
vary widely among tissues, cells and subcellular compartments
and because local concentrations vary on a millisecond timescale,
the availability of probes with a variety of ATP affinity ranges, fast
ATP binding and response kinetics seem features necessary for
future ATP probes (Rajendran et al., 2016).
Mitochondrial Respiration
In the ETC the production of ATP is directly coupled
to the consumption of molecular oxygen (O2). Quantifying
intracellular O2 consumption (respirometry) is therefore a
direct estimate of the mitochondrial respiratory activity and
as such another crucial readout for the mitochondrial and
cellular health status (Brand and Nicholls, 2011). The classical
respirometry approaches are electrode-based systems like the
Seahorse R© XF Analyzers (Smolina et al., 2017) and the Oroboros
O2k-Fluo Respirometer (Makrecka-Kuka et al., 2015). These
are highly sensitive devices to quantify intracellular oxygen
levels in living cells. However, these approaches lack spatial
resolution to distinguish O2 concentration at the single cell
or subcellular level.
Imaging approaches using microscopy have been developed
also for the quantification of O2. These are mostly based on
oxygen induced quenching of phosphorescence or luminescence
generated by cell-permeable probes that all still are in an
experimental phase. Extensive description of the pitfalls,
advantages and opportunities were summarized by Dmitriev and
Papkovsky (2015) and more recently by Yoshihara et al. (2017).
Despite all the research, further development is still necessary
before O2 imaging will be available for routine use (Dmitriev and
Papkovsky, 2015). Therefore, we still consider electrode-based
systems the benchmark to quantify intracellular O2 consumption.
HUMAN CELL MODELS IN
MITOCHONDRIAL RESEARCH
The choice of an appropriate cell model, recapitulating robust
pathological read-out appears to be the first challenge and goal
to achieve (Breuer et al., 2013) when evaluating mitochondrial
contribution to disease.
Because cell specific metabolism is highly regulated at the
genetic, transcriptional and post transcriptional level, every
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cell type has different energetic requirements. Therefore,
mitochondrial physiopathology differs substantially between
different cell models depending from their tissue of origin
(Smeitink et al., 2006). Mitochondrial functionality can be
differentially regulated, induced or even suppressed also
depending from environmental factors such as nutrient
availability, oxygen condition, differentiation, passage number
and many other variables that should therefore be tightly
controlled (Benard et al., 2010).
The human cell models most commonly used in
mitochondrial research, with their advantages and disadvantages
are discussed in the next paragraphs and listed in Table 2.
Primary Culture
Primary cells are a good model to study disease-related
phenotypes, since they do not undergo genetic manipulation,
present the biological aging of the patients and are
usually sampled at the moment of diagnosis. When using
patients-derived primary cells, the use of adequate control cells
to compare and normalize data to is crucial. The common
approach is to use samples derived from healthy gender- and
age-matched volunteers. However, because of the different
genetic backgrounds between any two individuals, cell-specific
non-pathological differences may be introduced. This makes
comparison of multiple control and patient cell lines in
parallel essential.
In mitochondrial research, the most used primary cell model
is skin fibroblasts. A review by Auburger et al. (2012) highlighted
some of the advantages and drawbacks of primary skin fibroblast
cultures. Easy availability from patients and matched controls
and robustness in culture, storage, and transport were identified
as some of the main advantages. In relation to microscopy,
fibroblasts are also ideal for imaging simply by epifluorescence
(non-confocal) microscopy. Thanks to their extremely flat
morphology and a relatively large size, imaging one single focal
plane is sufficient to have most of the cell body in focus. However,
in mitochondrial disease, the cells with high bioenergetic
requirements and concomitant reliance on mitochondrial ATP
generation such as neurons, retinal, muscle cells, and in particular
cardiomyocyte are often the most affected and often associated
with malfunction of the corresponding organs (Breuer et al.,
2013; Liang et al., 2014). Therefore, one of the possible concerns
using fibroblasts in mitochondrial research regards the fact that
these cells do not originate from a defective organ. Indeed, despite
the presence of the pathogenic mutation, aberrant phenotypes
are not always observed in primary fibroblasts in classical
culture regimes. Therefore, different stress conditions have
been used by the research community to enhance pathological
symptoms and study the dysfunctions. Culture medium in
which galactose replaces glucose to enforce ATP production
to rely on mitochondrial metabolism (Robinson et al., 1992;
Rossignol et al., 2004; Iannetti et al., 2018) and buthionine
sulfoximine treatment to reduce glutathione, the main cellular
antioxidant (Shrader et al., 2011; Beyrath et al., 2018), are
two well-known strategies to induce or enhance pathological
mitochondrial phenotypes.
Cytoplasmic Hybrids (Cybrids)
Cytoplasmic hybrids (cybrids) are generated by fusing
nuclear-depleted cells derived from patients carrying mtDNA
mutations with cell lines in which the mtDNA has been
removed (so called Rho Zero Cells). The cybrids model has
been traditionally used to study mtDNA mutations and dissect
the relationship between mtDNA and phenotype alterations
(King and Attardi, 1989; Swerdlow, 2007; Wilkins et al., 2014).
By introducing the patient-derived mtDNA into a healthy
TABLE 2 | Human cell models used in mitochondrial research.
Pros Cons
Primary fibroblasts
- relatively easy availability from patients and matched controls
- easy isolation
- robustness in culture, storage, and transport
- low cost
- not genetically modified
- flat morphology and a relatively large size allow non-confocal imaging
- present the biological aging of the patients and are usually sampled
at the moment of diagnosis
- do not originate from the defective organs
- stress conditions are often necessary to enhance pathological
symptoms
- slow proliferation
- require large surface to grow significant number of cells
- can be used only for a limited number of passages
Cybrids
- relationship between mtDNA and phenotype can be studied
- robustness in culture, storage, and transport
- low cost
- nuclear-mitochondrial interactions are lost
- cancer-like glycolytic bioenergetics profile
- genetics aberrations
- useful only to study mitochondrial encoded mutations
iPSc and iPSc-derived
- mimic the defective organs
- originate from the specific patient
- pathological symptoms are usually present
- derived from easily accessible patient material (skin, blood, urine)
- can be differentiated into virtually any cell type of the body
- open possibilities for precision medicine approaches
- genetically modified: mutagenesis risk
- suboptimal standardization
- mtDNA mutations can impair cellular reprogramming to iPSCs and
differentiation
- costly and timely procedure
- iPSc heterogeneity can mask actual disease-associated phenotypes
- low yield of differentiated cells
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nuclear background, it is possible to dissect whether a certain
mutation is sufficient to cause bioenergetics or cellular defects,
making cybrids instrumental in dissecting the precise cellular
and molecular consequences of a specific mtDNA mutations
and the field of mtDNA-related diseases has greatly benefitted
from this model.
Unfortunately, the patient-specific interplay between
mitochondrial and nuclear genomes, which may play a
contributing role in the OXPHOS dysfunction manifestation
(Spinazzola and Zeviani, 2009), is lost in the cybrids model.
Another disadvantage of cybrids, like other common immortal
cell lines, is that they usually present genetic aberrations and
relay on a glycolytic bioenergetics and not on OXPHOS like
disease affected cells (Abramov et al., 2010). Moreover, cybrids
are useful only to study mitochondrial encoded mutations and
not for nuclear ones.
iPSCs and Differentiated iPSCs-Derived
Cells
Human induced pluripotent stem cells (iPSCs) are obtained from
somatic cells through the process of cellular reprogramming
(Takahashi et al., 2007). iPSCs can be derived from easily
accessible patient material (skin, blood, urine) and can be
coaxed to differentiate into virtually any cell type of the
body. Diseases affecting the nervous system, like mitochondrial
disorders, may particularly benefit from iPSC research, since
the affected patient tissue is not readily available for testing.
Genome editing techniques, such as CRISPR/Cas9, combined
with iPSCs technology have opened unprecedented opportunities
in manipulating nDNA to induce or correct specific mutations
of interest. It is possible to generate isogenic iPSCs, which
carry the same background (from a control or a patient
individual) and differ only in one single disease-causing mutant
gene (Grobarczyk et al., 2015). However, genome editing
technology is well established only for nuclear DNA (Komor
et al., 2017), as engineering of mitochondrial DNA still remain
technically challenging (Patananan et al., 2016; Gammage
et al., 2017). iPSCs can be applied in compound screens
aimed at identifying treatments for mitochondrial diseases
(Inak et al., 2017). In fact, one of the key advantages of
iPSC-based models is that they may allow a precision medicine
approach (Gibbs et al., 2018).
On the other hand, iPSCs also hold disadvantages. Some
studies reported that mtDNA MELAS mutations impair
cellular reprogramming to iPSCs (Yokota et al., 2015). Cellular
fate-determination processes may also be affected, in particular
neuronal and cardiac lineage commitment (Folmes et al.,
2013; Hatakeyama et al., 2015; Yokota et al., 2017). This may be
regarded as a possible readout for mitochondrial dysfunction, but
also as a technical complication to generate patient iPSC derived
cell lines. Furthermore, the generation of iPSCs is costly and time
consuming. It is now apparent that different iPSC lines can be
very heterogeneous, thereby masking actual disease-associated
phenotypes. Unfortunately, the reprogramming process itself
can also induce nuclear and mitochondrial DNA alterations
(Pera, 2011; Perales-Clemente et al., 2016), and therefore the
genome of all iPSC lines needs to be carefully monitored.
The differentiation of iPSCs is time-consuming and often
very challenging in obtaining robust and homogenous
differentiated progeny (Saha and Jaenisch, 2010), resulting
in a small number of obtained differentiated cells that can
limit the scalability and the high-throughput applications
of iPSC-derived cells. Finally, given that iPSCs rejuvenate
the state of mitochondria (Lisowski et al., 2018) and the
aging-associated epigenetic signature (Mertens et al., 2018), it
has been suggested to circumvent the generation of iPSCs by
using a direct reprogramming approach (Vierbuchen et al.,
2010). In this approach, patient-derived fibroblasts can be
directly converted into neurons without going through the
state of iPSCs, thereby retaining the aging signature (Mertens
et al., 2015; Victor et al., 2018). Nonetheless, also directly
reprogrammed cells carry disadvantages as they need to
be generated newly continually and cannot be easily used
for genome editing.
HIGH-CONTENT SCREENING
APPLICATIONS TO STUDY
MITOCHONDRIAL FUNCTIONS
High-content screening (HCS) is defined as a cell-based
phenotypic approach where readouts are imaged by
multiplexed and automated microscopy (Zanella et al.,
2010; Pegoraro and Misteli, 2017); this is also referred to as
cellomics (Taylor, 2007).
Because of the fast developments of technologies,
probes and applications and the upcoming field of iPSCs
technology generating faithful cell disease models, the field
of cellomics is now on the brink of catching up with the
other–omics approaches.
Already in 2007 an HCS method was developed combining
1ψ analysis with other cellular parameters measured in
human liver carcinoma cells (HepG2) grown in a microfluidics
device (Ye et al., 2007). Also performed in HepG2 cells an
HCS assays has been described to screen drugs based on
six parameters among which 1ψ and mitochondrial area
(Persson et al., 2013) or intracellular redox state (Ye et al.,
2007; Donato et al., 2012). A cellomics liver toxicity assay
using iPSC-derived hepatocytes was recently published that
focuses on drug development and toxicity testing, studying
mitochondrial parameters as indicators of cellular health
(Sirenko and Cromwell, 2018). Leonard et al. addressed more
technical aspects of HCS application development combining
the quantitative analysis of mitochondrial morphology and 1ψ
in living photoreceptor cells with supervised machine learning
(Leonard et al., 2015). In 2016 we described a detailed protocol
to optimize multiplexed high-content analysis of mitochondrial
morphofunction in primary human skin fibroblasts showing
potential implementation of the protocol to HCS format
(Iannetti et al., 2016). With this same cell type a high-content
method was also developed to combine the study of cellular
ROS levels and mitochondrial morphofunction (Sieprath et al.,
2016). Other cellomics applications focused instead primarily on
the identification of mitochondrial pathological phenotypes to
Frontiers in Genetics | www.frontiersin.org 6 March 2019 | Volume 10 | Article 131
fgene-10-00131 February 27, 2019 Time: 17:26 # 7
Iannetti et al. Live-Imaging of Mitochondrial Function
evaluate their contribution to disease. Among these, a strategy
based on iPSC-derived NPCs of mtDNA patients in which a
1ψ–related pathological phenotype was identified and used to
screen a compound-library (Lorenz et al., 2017). A 384-well
plates based HCS application, identifying reduced 1ψ and
mitochondrial morphology aberrations in iPSC-derived neurons
from Parkinson’s disease patients as compared to controls, was
also recently published (Little et al., 2018).
All these studies show the applicability of mitochondrial
morphofunction and ROS analysis as robust HCS/cellomics
applications. These will likely in the near future be complemented
with fluorescent imaging technologies to detect ATP and oxygen
consumption, which, to the best of our knowledge, have not been
explored yet.
CONCLUSION
Cellomics represents a powerful technology, already established
in many research labs, to study in an unbiased manner
mitochondrial functions monitoring multiple readouts, portable
to different cells models and able to provide valuable
insight in mitochondrial phenotypes and their contribution
to disease.
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